Structure-based discovery of LpxC inhibitors.
Zhang, J., Chan, A., Lippa, B., Cross, J.B., Liu, C., Yin, N., Romero, J.A., Lawrence, J., Heney, R., Herradura, P., Goss, J., Clark, C., Abel, C., Zhang, Y., Poutsiaka, K.M., Epie, F., Conrad, M., Mahamoon, A., Nguyen, K., Chavan, A., Clark, E., Li, T.C., Cheng, R.K., Wood, M., Andersen, O.A., Brooks, M., Kwong, J., Barker, J., Parr, I.B., Gu, Y., Ryan, M.D., Coleman, S., Metcalf, C.A.(2017) Bioorg Med Chem Lett 27: 1670-1680
- PubMed: 28302397 
- DOI: https://doi.org/10.1016/j.bmcl.2017.03.006
- Primary Citation of Related Structures:  
5N8C - PubMed Abstract: 
The emergence and spread of multidrug-resistant (MDR) Gram negative bacteria presents a serious threat for public health. Novel antimicrobials that could overcome the resistance problems are urgently needed. UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) is a cytosolic zinc-based deacetylase that catalyzes the first committed step in the biosynthesis of lipid A, which is essential for the survival of Gram-negative bacteria. Our efforts toward the discovery of novel LpxC inhibitors are presented herein.
Organizational Affiliation: 
Cubist Pharmaceuticals Inc., 65 Hayden Avenue, Lexington, MA 02421, USA. Electronic address: jackzhang49@yahoo.com.